Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 4/20 | 0.48 |
| ▸ | REN | P00797 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | PEPD | P12955 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
| ▸ | THPO | P40225 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.48 |
| ▸ | DPP4 | P27487 | 2/20 | 0.43 |
| ▸ | FAP | Q12884 | 1/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30159321 | 0.93 | CAPN1 (0.43) | ACERENLMNAHSD17B10KDM4E | |
| SCHEMBL30395259 | 0.91 | ACE (0.48) | ACERENLMNAHSD17B10KDM4E | |
| SCHEMBL30817465 | 0.91 | ACE (0.52) | ACERENLMNAHSD17B10KDM4E | |
| SCHEMBL30169755 | 0.90 | ACE (0.47) | ACERENLMNAHSD17B10KDM4E | |
| SCHEMBL29408003 | 0.90 | DPP4 (0.45) | ACEDPP4FAPDPP8DPP9 | |
| SCHEMBL29765255 | 0.89 | CAPN1 (0.47) | ACERENLMNAHSD17B10KDM4E | |
| SCHEMBL29765176 | 0.85 | CAPN1 (0.47) | ACERENLMNAHSD17B10KDM4E | |
| SCHEMBL29765105 | 0.85 | CAPN1 (0.47) | ACERENLMNAHSD17B10KDM4E | |
| SCHEMBL29765170 | 0.85 | CAPN1 (0.47) | ACERENLMNAHSD17B10KDM4E | |
| SCHEMBL29630804 | 0.84 | ACE (0.44) | ACERENLMNAHSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416714-A1 | USE OF THERAPEUTIC ENZYME FUSION PROTEIN IN PREVENTION AND TREATMENT OF NEUROPATHY CAUSED BY OR ACCOMPANIED BY FABRY DISEASE | HANMI PHARM. CO., LTD (KR) | 2023-12-28 | — | — | US | disclosed |
| US-20230405093-A1 | USE OF THERAPEUTIC ENZYME FUSION PROTEIN IN PREVENTION AND TREATMENT OF RENAL DISEASES CAUSED BY OR ACCOMPANIED BY FABRY DISEASE | HANMI PHARM. CO., LTD. (KR) | 2023-12-21 | — | — | US | disclosed |
| EP-4245311-A1 | USE OF THERAPEUTIC ENZYME FUSION PROTEIN FOR PREVENTING AND TREATING KIDNEY DISEASE CAUSED OR ACCOMPANIED BY FABRY'S DISEASE | Hanmi Pharm. Co., Ltd. (KR) | 2023-09-20 | — | — | EP | disclosed |
| EP-4245310-A1 | USE OF THERAPEUTIC ENZYME FUSION PROTEIN IN PREVENTING AND TREATING NEUROPATHY ATTRIBUTED TO OR ASSOCIATED WITH FARBRY'S DISEASE | Hanmi Pharm. Co., Ltd. (KR) | 2023-09-20 | — | — | EP | disclosed |
| CN-116635055-A | Pharmaceutical composition for preventing or treating lupus-related diseases comprising GIP derivative or long-acting conjugate thereof | 韩美药品株式会社 | 2023-08-22 | — | — | CN | disclosed |
| CN-116583533-A | GIP derivative, long-acting conjugate thereof and pharmaceutical composition comprising the same | 韩美药品株式会社 | 2023-08-11 | — | — | CN | disclosed |
| CN-116419759-A | Use of therapeutic enzyme fusion proteins for the prevention and treatment of neurological disorders caused by or associated with fabry disease | 韩美药品株式会社 | 2023-07-11 | — | — | CN | disclosed |
| CN-116419760-A | Use of therapeutic enzyme fusion proteins for the prevention and treatment of kidney diseases caused by or associated with fabry disease | 韩美药品株式会社 | 2023-07-11 | — | — | CN | disclosed |
| WO-2022103221-A1 | USE OF THERAPEUTIC ENZYME FUSION PROTEIN FOR PREVENTING AND TREATING KIDNEY DISEASE CAUSED OR ACCOMPANIED BY FABRY'S DISEASE | 한미약품 주식회사 | 2022-05-19 | — | — | WO | disclosed |
| WO-2022103220-A1 | USE OF THERAPEUTIC ENZYME FUSION PROTEIN IN PREVENTING AND TREATING NEUROPATHY ATTRIBUTED TO OR ASSOCIATED WITH FARBRY'S DISEASE | 한미약품 주식회사 | 2022-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416714-A1 | USE OF THERAPEUTIC ENZYME FUSION PROTEIN IN PREVENTION AND TREATMENT OF NEUROPATHY CAUSED BY OR ACCOMPANIED BY FABRY DISEASE | PMP22, FAP, GAA | ACE 292/4885REN 1293/4885LMNA 2631/4885 |
| US-20230405093-A1 | USE OF THERAPEUTIC ENZYME FUSION PROTEIN IN PREVENTION AND TREATMENT OF RENAL DISEASES CAUSED BY OR ACCOMPANIED BY FABRY DISEASE | GAA, MME, ENPEP | ACE 60/4885REN 29/4885LMNA 1764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.